Your session is about to expire
← Back to Search
Enzyme Inhibitor
ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian Cancer
Phase < 1
Waitlist Available
Led By Evthokia Hobbs, M.D.
Research Sponsored by OHSU Knight Cancer Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 1 to 30 days after last dose of study intervention
Awards & highlights
No Placebo-Only Group
Summary
This trial tests ZN-c3, a medicine that blocks enzymes needed for cancer cell growth, in patients with advanced or metastatic triple-negative breast cancer or ovarian cancer. By blocking an important enzyme, ZN-c3 aims to stop cancer cells from growing and spreading.
Eligible Conditions
- Breast cancer
- Ovarian Cancer
- Fallopian Tube Cancer
- Peritoneal Cancer
- Peritoneal Carcinoma
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ day 1 to 30 days after last dose of study intervention
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 1 to 30 days after last dose of study intervention
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Incidence of adverse events
Percent decrease of phosphorylated CDK1 and/or Ki67, or p-HH3, or p-CHK1 in tumor cells
Secondary study objectives
CBR for ovarian cancer
Clinical benefit rate (CBR)
Overall survival
+2 moreOther study objectives
Cellular and molecular characteristics
ZN-c3 tumor and plasma concentrations
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Treatment (wee1 inhibitor ZN-c3)Experimental Treatment1 Intervention
Patients receive Wee1 inhibitor ZN-c3 PO QD on days 1-21. Treatment repeats every 21 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
Find a Location
Who is running the clinical trial?
Oregon Health and Science UniversityOTHER
1,006 Previous Clinical Trials
7,414,112 Total Patients Enrolled
OHSU Knight Cancer InstituteLead Sponsor
236 Previous Clinical Trials
2,089,580 Total Patients Enrolled
Evthokia Hobbs, M.D.Principal InvestigatorOHSU Knight Cancer Institute
Zahi Mitri, MD, MSPrincipal InvestigatorOHSU Knight Cancer Institute
4 Previous Clinical Trials
145 Total Patients Enrolled